K-Cab Adverse Reactions

A total of 5 clinical studies were conducted with erosive gastroesophageal reflux disease and non-erosive gastroesophageal reflux disease and gastric ulcer patients. 360 patients were treated with tegoprazan 50 mg. Adverse reactions and adverse drug reactions (marked with *) reported during the clinical trials are as following: Common adverse reactions reported (≥1%) in tegoprazan 50 mg treatment group are presented in Table 5. (See Table 5.)

Click on icon to see table/diagram/image

Less common adverse reactions reported in <1% patients after administration of tegoprazan 50 mg from clinical studies are presented in Table 6. (See Table 6.)

Click on icon to see table/diagram/image

Two clinical studies were conducted in patients with peptic ulcer and/or chronic atrophic gastritis who were positive for H. pylori. 314 patients were treated with tegoprazan 50 mg, in combination with amoxicillin 1 g and clarithromycin 500 mg. Adverse reactions and adverse drug reactions (marked with *) reported during the clinical trial is as following: Common adverse reactions events reported (≥1%) in tegoprazan 50 mg in combination with amoxicillin 1 g and clarithromycin 500 mg treatment group are presented in Table 7. (See Table 7.)

Click on icon to see table/diagram/image

Less common adverse reactions reported in <1% patients after administration of tegoprazan 50 mg in combination with amoxicillin 1 g and clarithromycin 500 mg from clinical study are presented in Table 8. (See Table 8.)

Click on icon to see table/diagram/image